Streetwise Reports' Article Archives — February 2021 back to current month (26)

Virtual HealthCare Tech Firm Contracts to Provide Patient Care Platform to US Nephrology Clinic (02/26/2021)

Reliq Health Technologies reported it signed a new agreement with a Texas-based nephrology clinic to provide its iUGO Care platform to patients with chronic kidney disease.


Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck (02/25/2021)

Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share.


Telehealth Tech Company Continues Rapid Growth in COVID-Changed Landscape (02/24/2021)

Reliq Health introduces iUGO Home services and just added a care management network in California with 50 clinics and over 500 physicians.


Analyst: All Systems Are Go for Testing, Testing and More Testing (02/24/2021)

This Dawson James report explains why ProPhase Labs is perfectly positioned to benefit from expanded COVID testing.


U.S. Cannabis Company 'Cashed Up with Catalysts Materializing' (02/24/2021)

The many reasons why Columbia Care is 'due for a catch-up trade' are discussed in an Echelon Capital Markets report.


Owens & Minor Shares Soar 36% After Firm Reports Record Q4 Earnings and Positive 2021 Outlook (02/24/2021)

Shares of Owens & Minor Inc. soared to a new 52-week high after the company reported Q4/20 and FY/20 financial results that were boosted by a 58% gain in global products revenue and increases in elective medical procedures.


Company's Antibiotic-Free Livestock Feed Product Shows Positive Results in Subclinical Mastitis Dairy Trial (02/22/2021)

Avivagen Inc. reported that data from a New Zealand OxC-betaT™ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal.


Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results (02/17/2021)

New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report.


Virtual HealthCare Tech Firm Contracts with California Network of 500+ Doctors and 50 Clinics (02/17/2021)

Reliq Health Technologies reported it signed a new contract with a care management network for its iUGO Care platform to deliver customized healthcare to senior citizens in the Asian-American community throughout California.


Digital Therapeutics Leader DarioHealth Makes a Critical Acquisition (02/17/2021)

Independent financial analyst Matt Badiali discusses DarioHealth's latest acquisition and what it means for the company's growth.


Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer (02/17/2021)

Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development.


PAVmed Shares Increase 28% after First US Patient Treated with CarpX Device for Carpal Tunnel Syndrome (02/16/2021)

PAVmed Inc. shares reached a new 52-week high after the company reported that the first patient in the U.S. was successfully treated with its CarpX® Device, a minimally invasive carpal tunnel release surgical instrument.


Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial (02/12/2021)

Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol.


ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook (02/12/2021)

Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results.


AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial (02/11/2021)

Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease.


Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT (02/10/2021)

Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients.


Pacific Biosciences Shares Rise 22% on $900 Million Investment from Japan's SoftBank (02/10/2021)

Shares of Pacific Biosciences of California traded to a new 52-week high after the firm reported that a Softbank Group subsidiary will invest $900 million to support its growth initiatives.


Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke (02/05/2021)

This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report.


Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases (02/05/2021)

The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report.


Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers (02/04/2021)

DELIC aims to become a leader in psychedelic health and wellness clinics.


Align Technology Shares Grind 12.5% Higher after Firm Posts Record Q4 Revenue of $834.5 Million (02/04/2021)

Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion.


Neurosciences Firm Provides Insight on Recent Alzheimer's/Amyloid Field Developments (02/03/2021)

ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class."


GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals (02/03/2021)

Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share.


Cassava Shares Triple After Interim Trial Data Shows Simufilam Improves Cognition and Behavior in Alzheimer's Disease (02/02/2021)

Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients.


Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT, the 'Spirit Molecule' (02/01/2021)

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.


Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics (02/01/2021)

Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share.


More Archives

2024Jun May Apr Mar Feb Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes